BridgeMD
New treatment option for High-risk Prostate Cancer
Official title Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.
ClinicalTrials.gov ID: NCT07357259
What this study is testing
- What it's testing
- Recent evidence suggests that both standard-time and delayed-time [⁶⁸Ga]Ga-PSMA PET acquisitions can reveal clinically relevant findings, and neither phase should be excluded a priori in routine practice. This study evaluates a streamlined dual-phase protocol consisting of: A standard whole-body PET/CT acquisition performed 60 minutes after radiotracer administration.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 and older, men only
You may be able to join if
- Newly diagnosed prostate cancer undergoing staging, or
- Biochemical recurrence following prior radical-intent therapy (surgery and/or radiotherapy), or
- High-risk prostate cancer, defined as Gleason Score ≥ 8 or PSA ≥ 20 ng/mL.
- Written informed consent and authorization for personal data processing.
You likely can't join if
- Genitourinary comorbidities that could interfere with imaging or interpretation.
- Intermediate- or low-risk prostate cancer.
- Delayed acquisition performed on a PET/CT scanner different from the standard acquisition.
- Additional PET/CT required due to artifacts compromising diagnostic quality (e.g., urinary retention, excessive motion).
- Patients previously enrolled who require repeat PET/CT as a new visit.
- Inability to provide informed consent or impaired decision-making capacity.
See the full eligibility criteria
- Newly diagnosed prostate cancer undergoing staging, or
- Biochemical recurrence following prior radical-intent therapy (surgery and/or radiotherapy), or
- High-risk prostate cancer, defined as Gleason Score ≥ 8 or PSA ≥ 20 ng/mL.
- Written informed consent and authorization for personal data processing.
- Genitourinary comorbidities that could interfere with imaging or interpretation.
- Intermediate- or low-risk prostate cancer.
- Delayed acquisition performed on a PET/CT scanner different from the standard acquisition.
- Additional PET/CT required due to artifacts compromising diagnostic quality (e.g., urinary retention, excessive motion).
- Patients previously enrolled who require repeat PET/CT as a new visit.
- Inability to provide informed consent or impaired decision-making capacity.
- Known hypersensitivity to the radiopharmaceutical or its components.
- Contraindications to PET/CT (e.g., severe claustrophobia, morbid obesity, inability to cooperate).
The study team makes the final eligibility decision.
Where it's taking place
- Bologna, Italy, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 30 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bologna, Italy, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.